Microbot Medical Inc. (NASDAQ:MBOT) Sees Large Growth in Short Interest

Microbot Medical Inc. (NASDAQ:MBOT) was the recipient of a significant growth in short interest in June. As of June 15th, there was short interest totalling 374,800 shares, a growth of 27.5% from the May 31st total of 293,900 shares. Based on an average daily volume of 2,570,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of Microbot Medical

An institutional investor recently bought a new position in Microbot Medical stock. Armistice Capital LLC acquired a new stake in shares of Microbot Medical Inc. (NASDAQ:MBOT) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 300,000 shares of the biotechnology company’s stock, valued at approximately $492,000. Armistice Capital LLC owned 2.56% of Microbot Medical at the end of the most recent reporting period. 16.30% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Microbot Medical in a research note on Monday, June 3rd.

Microbot Medical Stock Performance

Shares of NASDAQ MBOT opened at $1.01 on Tuesday. The company has a market cap of $14.54 million, a P/E ratio of -1.13 and a beta of 1.68. Microbot Medical has a 52-week low of $0.86 and a 52-week high of $2.97. The firm’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.17.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Wednesday, May 15th. The biotechnology company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). As a group, analysts forecast that Microbot Medical will post -0.66 EPS for the current fiscal year.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.